Amarin Co. plc Sees Unusually Large Options Volume (AMRN)
Shares of Amarin Co. plc (NASDAQ:AMRN) was the target of unusually large options trading activity on Monday. Investors bought 24,205 call options on the company, AnalystRatingsNetwork reports. This is an increase of approximately 183% compared to the typical daily volume of 8,556 call options.
A number of research firms have recently commented on AMRN. Analysts at Goldman Sachs Group Inc. initiated coverage on shares of Amarin Co. plc in a research note to investors on Tuesday, September 17th. They set a “neutral” rating on the stock. Separately, analysts at JPMorgan Chase & Co. cut their price target on shares of Amarin Co. plc from $12.00 to $11.00 in a research note to investors on Friday, September 13th. They now have an “overweight” rating on the stock. Finally, analysts at Aegis reiterated a “buy” rating on shares of Amarin Co. plc in a research note to investors on Friday, September 13th. They now have a $30.00 price target on the stock. Three research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $13.54.
Shares of Amarin Co. plc (NASDAQ:AMRN) traded up 1.25% during mid-day trading on Monday, hitting $7.27. The stock had a trading volume of 8,298,972 shares. Amarin Co. plc has a 1-year low of $5.12 and a 1-year high of $12.96. The stock has a 50-day moving average of $6.51 and a 200-day moving average of $6.51. The company’s market cap is $1.255 billion.
Amarin Co. plc (NASDAQ:AMRN) last released its earnings data on Thursday, August 8th. The company reported ($0.26) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.38) by $0.12. The company had revenue of $5.50 million for the quarter. On average, analysts predict that Amarin Co. plc will post $-1.36 earnings per share for the current fiscal year.
Amarin Corporation plc (NASDAQ:AMRN) is a late-stage biopharmaceutical -company with expertise in lipid science focused on the treatment of cardiovascular disease.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.